CTNM
Contineum Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.79
+1.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | 50.0M | — |
| Cost of Revenue | — | — | 258.0K | — | — |
| Gross Profit | — | — | (258.0K) | 50.0M | — |
| Operating Expenses | |||||
| R&D Expense | 53.1M | 51.5M | 38.2M | 27.6M | 16.9M |
| SG&A Expense | 19.3M | 16.5M | 12.5M | 6.3M | 5.8M |
| General & Admin Expense | 19.3M | 16.5M | 12.5M | 6.3M | 5.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | 32.2M | — |
| Total Operating Expenses | 72.4M | 68.1M | 50.6M | 66.1M | 22.7M |
| Cost and Expenses | 51.4M | 68.1M | 50.9M | 66.1M | 22.7M |
| Operating Income (EBIT) | (72.4M) | (68.1M) | (50.9M) | (16.1M) | (22.7M) |
| Non-Operating | |||||
| Interest Income | 9.2M | 8.2M | 8.9M | 4.6M | 761.0K |
| Interest Expense | — | — | — | 208.0K | 388.0K |
| Net Interest Income | 6.9M | 8.2M | 8.9M | 4.4M | 373.0K |
| Other Non-Op Income/Expense | 8.9M | 8.1M | 8.6M | 39.2M | (1.5M) |
| Non-Operating Income (excl Interest) | — | — | (8.6M) | (39.5M) | 1.1M |
| EBT (Pre-Tax Income) | (63.5M) | (60.0M) | (42.3M) | 23.2M | (24.3M) |
| Income Tax Expense | — | — | — | 450.0K | — |
| Bottom Line | |||||
| Net Income | (63.5M) | (60.0M) | (42.3M) | 22.7M | (24.3M) |
| Earnings from Cont. Ops | (63.5M) | (60.0M) | (42.3M) | 22.7M | (24.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (63.5M) | (60.0M) | (42.3M) | 22.7M | (24.3M) |
| Per Share | |||||
| Basic EPS | ($1.77) | ($2.17) | ($1.63) | $0.13 | ($0.97) |
| Diluted EPS | ($1.77) | ($2.17) | ($1.63) | $0.13 | ($0.97) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $1.99 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 38.4M | 27.7M | 25.9M | 25.1M | 25.1M |
| Diluted Shares Outstanding | 38.4M | 27.7M | 25.9M | 25.1M | 25.1M |
| Profitability Metrics | |||||
| EBITDA | (72.1M) | (67.7M) | (42.0M) | 23.6M | (23.5M) |
| D&A | 302.0K | 323.0K | 258.0K | 195.0K | 329.0K |
| EBIT | (51.4M) | (68.1M) | (42.3M) | 23.4M | (23.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026